focus -WSS

focus

author：leisure time 2025-08-12 09:12:37 - browse：37713

A person picking up medication at a drive through pharmacy window – biotech and pharma coverage from STAT — Adobe

On Tuesday morning, the Department of Health and Human Services unveiled its long-awaited list of the 10 medicines that will be subject to price negotiation in 2026 under the Inflation Reduction Act.

This will mark the first time that Medicare, the government program for paying for health care for older Americans, will have any ability to use its vast size to negotiate for lower prices. It’s not yet clear how big the discounts on these 10 drugs will be, or even if the law will hold up to multiple legal challenges from the pharmaceutical industry. It’s also not clear, as critics from the drug industry have noted, whether any savings to the government will be passed on to consumers.

Still, the naming of 10 medicines is a milestone, and a point to start appraising the impact of the law. The landscape here is complicated. No one really knows how the IRA’s price negotiation process will play out over the short and long term, and many companies who had products named were spared in other ways, with products many industry watchers expected to see on the list absent. Here is STAT’s assessment of who has won and lost.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban
Next article： 'Vaccine

entertainment

hotspot

WSS

'Vaccine

Study fuels hope CAR

CDC advisory group OKs chikungunya vaccine

NIH chief: government has fallen behind pharma on clinical trials

5 ways to address the shortage of health care workers

Ventyx halts psoriasis drug development after lackluster trial results

entertainment

focus

hotspot

In Memoriam: Notable people who died in 2023

Medical school prerequisites are outdated

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Change Healthcare cyberattack shows risk of industry consolidation

Walensky prepares to leave CDC — and Congress — behind

Type 2 diabetes prevention programs work at large scale: study

The high cost of giving birth even with insurance

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

Alkermes shareholders re

Healthy food access boosts outcomes in two studies

leisure time

Medicare’s new pay boost for primary care is angering specialists

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

Cancer diagnosis changes perspective doctor, former hospital CEO

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Carbon Health diabetes program, a test of data

STAT Madness 2024: Meet the contenders

focus

entertainment

hotspot

leisure time